ClinicalTrials.gg
TerminatedNCT04421378Updated Dec 16, 2024Results posted

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

A Phase 1/2 interventional study of Selinexor and Temozolomide (TMZ) in Glioblastoma Multiforme, sponsored by Karyopharm Therapeutics Inc. Terminated at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Karyopharm Therapeutics Inc · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
55th of 221
74 · median 41
Started
2020
with 9 others
Phase 1/2
40 of 232
7 open now
Registered
199th of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 55th largest by enrollment of the 221 interventional ones that give a count, is one of 10 that started in 2020, is one of 40 in phase 1/2, and was the 199th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C).

  • Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT
  • Arm B: evaluating the combination of selinexor with radiation therapy and temozolomide (TMZ) (S-TRT) in nGBM participants with methylated-O6-methylguanine-DNA-methyltransferase (mMGMT)
  • Arm C: evaluating the combination of selinexor with lomustine (or carmustine, if lomustine is not available) (S-L/C) in rGBM participants regardless of MGMT status
  • Arm D: evaluating the combination of selinexor with bevacizumab in rGBM participants regardless of MGMT status
  • Arm E: evaluating the combination of selinexor with tumor treating fields (TTField) in rGBM participants regardless of MGMT status
03

Conditions studied

  • Glioblastoma Multiforme

Browse trials for

Keywords

  • nGBM
  • rGBM
  • GBM
  • Temozolomide
  • Lomustine
  • KPT-330
  • XPOVIO
  • Selinexor
  • Newly diagnosed glioblastoma multiforme
  • Recurrent glioblastoma multiforme
  • Bevacizumab
  • TTField
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written in accordance with federal, local, and institutional guidelines.
  • Age ≥18 years at the time of informed consent and ≥22 year for Arm E.
  • confirmed glioblastoma (including all histological variants; documentation to be provided) that are newly diagnosed (for Arms A and B) or disease (for Arm C, D and E) after 1 to 2 (RT ± TMZ or RT ± TMZ in combination with other drug) (surgical resection of recurrent disease allowed). For Arms A and B, MGMT status should be available.
  • Prior therapy:

    1. Arms A and B: participants who have not received RT or any systemic therapy for brain tumor and must be eligible for definitive external beam RT and TMZ
    2. Arm C, D and E: participants must have received prior treatment with RT with or without TMZ and only 1 prior line of therapy (RT ± TMZ in combination with other drug is allowed).
  • according to RANO/modified RANO guidelines is required only for Arm C, D and E; it is not required for Arms A or B.
  • Participants enrolling into Arms C, D, and E must be on a stable or decreasing dose of (or none) for at least 5 days prior to the baseline magnetic resonance imaging (MRI).
  • Performance Score (KPS) ≥70 (for Arms A and B) and 60 (for Arms C, D, and E).
  • Participants must have adequate organ function ≤2 weeks of study treatment as defined by the following laboratory criteria:

    1. Hematological function ≤7 days prior to Cycle 1 Day 1 (C1 D1): (ANC) ≥1.5*10\^9 per Liter (/L); count ≥150*10\^9/L; and (Hb) ≥10.0 gram per deciliter (g/dL). Transfusion is not allowed within 7 days prior to C1 D1
    2. Hepatic function: ≤2*the (ULN), (ALT) ≤2.5*ULN, aspartate transaminase (AST) ≤2.5*ULN; unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be \<4*ULN
    3. Renal function: calculated () or measured creatinine clearance ≥30 milliliter per minute (mL/min)
  • Female participants of must have a negative serum pregnancy test at Screening and agree to use highly effective methods of throughout the study and for 6 months following the last dose of study treatment.
  • Fertile male participants who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 6 months following the last dose of study treatment.
  • For Arms A and B: participants must have had surgery and/or not greater than [>] 8 weeks prior to initial screening.
  • Participants must consent to provide tumor tissue and blood samples to be used for future molecular testing for correlative studies.
  • Limited to supratentorial disease for Arm E only.

Exclusion criteria

Exclusion Criteria

  • Participants who are receiving any other agents and /or have had prior therapy including:

For Arms A and B only:

  1. Participants who have previously received RT to the brain
  2. Participants who received chemotherapy for the treatment of their glioma
  3. Participants who are being treated with implanted Gliadel wafers

    For Arm C:

  4. Prior nitrosoureas

    For Arms C, D, and E:

  5. \<4 weeks from prior TMZ or other chemotherapy, or \<4 weeks or 5 half-lives (whichever is shorter) for investigational agents prior to start of study treatment
  6. Prior treatment bevacizumab or other direct Vascular endothelial growth factor/Vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors. For any questions of the definition of a direct VEGF/VEGFR inhibitor, consult the study Medical Monitor
  7. Any AE which has not recovered to Grade \<=1, or returned to baseline, related to the previous GBM therapy, except alopecia, and some other Grade 2 AEs that have been stabilized (upon Medical Monitor approval)

    • Participants who are being treated or plan to be treated during this study with TTField for participants in Arms A to D.
    • Major surgery \<2 weeks prior to the start of study treatment for Arms A to C and E, \<4 weeks for Arm D.
    • History of allergic reactions attributed to compounds of similar chemical or biological composition to selinexor or other study treatment.
    • Participants must not have significantly diseased or obstructed gastrointestinal tract malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medication.
    • Participants with coagulation problems and medically significant bleeding in the month prior to start of treatment (peptic ulcers, epistaxis, intracranial hemorrhage, spontaneous bleeding). Prior history of deep vein thrombosis or pulmonary embolism is not exclusionary.
    • Currently pregnant or breastfeeding.
    • For Arms A and B: participants with pre-existing known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome.
    • Any life-threatening illness, active medical condition, organ system dysfunction, or serious active psychiatric issue which, in the Investigator's opinion, could compromise the participant's safety or the participant's ability to remain compliant with study procedures.
    • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable even if parenteral.
    • Participants with mutated isocitrate dehydrogenase (IDH) should be excluded for Phase 2.
    • For participants in Arm C, Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLCO) below 70% of predicted.
    • For Arm E: implanted active electronic medical devices such as programmable intraventricular shunts, spinal cord, vagus nerve or deep brain stimulators, pacemakers or implantable automatic defibrillators, skull defect (i.e. missing bone with no replacement), sensitivity to conductive hydrogels as used in (ECGs), an underlying serious scalp condition that may interfere with placement of arrays, or bullet fragments, or documented arrhythmias.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Phase 1: Arm A: Selinexor+Radiation Therapy

    Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.

    Drug: Selinexor · Radiation: Standard Fractionated Radiation therapy (RT)

  • Active comparator
    Arm A Control: Temozolomide+Radiation Therapy

    Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m\^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.

    Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)

  • Experimental
    Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy

    Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.

    Drug: Selinexor · Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)

  • Active comparator
    Arm B Control: Temozolomide+Radiation Therapy

    Participants with nGBM mMGMT will receive 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.

    Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)

  • Experimental
    Arm C: Selinexor+Lomustine/Carmustine

    Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m\^2 of lomustine or 150-200 mg/m\^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.

    Drug: Selinexor · Drug: Lomustine (CCNU) · Drug: Carmustine

  • Active comparator
    Arm C Control: Lomustine/Carmustine

    Participants with rGBM uMGMT or mMGMT will receive 110 mg/m\^2 of lomustine or 200 mg/m\^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.

    Drug: Lomustine (CCNU) · Drug: Carmustine

  • Experimental
    Arm D: Selinexor+Bevacizumab

    Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.

    Drug: Selinexor · Drug: Bevacizumab

  • Experimental
    Arm E: Selinexor+TTField

    Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.

    Drug: Selinexor · Device: TTField

Interventions

  • Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

    Also known as: KPT-330, XPOVIO

  • Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral

    Also known as: Temodar

  • Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral

  • RadiationStandard Fractionated Radiation therapy (RT)

    Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

  • Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous

  • DeviceTTField

    Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.

  • Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Phase 1a and 1b: Maximum Tolerated Dose of Selinexor

    MTD was defined as highest dose of selinexor in at which no more than one of six participants experienced a dose-limiting toxicity (DLT). DLT was based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: At Cycle 1 (up to 42 days)

  2. Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor

    The RP2D was determined by SRC, based on the MTD and the totality of efficacy and safety data of Phase 1a dose escalation study. RP2D was determined based on the totality of the available safety, efficacy, pharmacokinetic/pharmacodynamic (PK/PD).

    Time frame: From Cycle 1 Day 1 up to 14 days after last dose (up to 15.41 months) (Each Cycle length = up to 42 days)

  3. Phase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEs

    TEAE: any event that was not present prior to initiation of study treatment or any event already present that worsened in either intensity or frequency following exposure to study treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose, resulted in death; was life threatening (i.e., an event in which participant was at risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death if it were more severe); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect. Important medical events that might not result in death, was life-threatening, or require hospitalization might be considered serious when, based upon appropriate medical judgment, they might jeopardize participant and might require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose of study treatment up to 30 days post last dose (Up to 16.41 months)

  4. Phase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months

    Progression defined as first occurrence of disease progression (PD) per modified Response Assessment in Neuro-Oncology (RANO) including both radiological PD and clinical deterioration. PD per RANO response criteria:1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death.

    Time frame: At 3 Months

  5. Phase 1a and 1b: Overall Survival (OS)

    OS was defined as the time from the date of randomization until death due to any cause or until lost to follow-up for all participants.

    Time frame: From date of randomization to the date of death due to any cause or until lost to follow-up (up to 20 months)

Secondary outcomes

  1. Phase 1a and 1b: Time to Progression (TTP)

    TTP was defined for participants as the duration from start of treatment to the date of PD, or death due to PD, whichever occurs first. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.

    Time frame: From first dose study treatment until progression or death due to progression (Up to 15.41 months)

  2. Phase 1a and 1b: Progressive Free Survival (PFS)

    Progression defined as first occurrence of PD per modified RANO including both radiological PD and clinical deterioration. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.

    Time frame: From first dose of study treatment until progression or death due to any cause (Up to 15.41 months)

  3. Phase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E

    ORR was defined as percentage of participants who achieve a CR or PR per modified RANO criteria. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments.

    Time frame: From first dose of study treatment until death due to any cause (Up to 15.41 months)

  4. Phase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E

    DCR: percentage of participants who achieve CR, PR, or stable disease (SD) per modified RANO criteria. CR: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids. 4) Stable or improved clinical assessments. PR: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3) Steroid dose should be same or lower compared with baseline scan. 4) Stable or improved clinical assessments. SD: 1) Does not qualify for CR, PR, or PD. 2) In event that corticosteroid dose was increased without confirmation of PD on neuroimaging, and subsequent follow-up imaging shows steroid increase was required because of PD, last scan considered to show SD was scan obtained when corticosteroid dose was equivalent to baseline dose.

    Time frame: From first dose of study treatment until death due to any cause (Up to 15.41 months)

  5. Phase 1a and 1b: Duration of Response (DOR) in Arm C, D and E

    DOR was defined as the time from the date of first evidence of objective response (CR or PR) until PD. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments. DOR was analyzed by Kaplan-Meier for participants who have achieved overall response (CR or PR).

    Time frame: From the date of first evidence of objective response until progression (Up to 15.41 months)

  6. Phase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor

    Cmax of Selinexor was reported.

    Time frame: Cycle 1 Day 1: 2, 4, and 6 hours post-dose (Cycle 1 length = up to 42 days)

07

Results

Posted Dec 16, 2024
Limitations and caveats
The trial was terminated during the Phase 1b portion of the trial as the initial responses to selinexor treatment were not supportive of continued investigation in glioblastoma, therefore there was no reporting of the Phase 2 outcomes.

Participant flow

This study was conducted at 18 sites in the United States and Canada. This study had three phases: Phase 1a, Phase 1b and Phase 2. The study was early terminated during the Phase 1b portion of the study as the initial responses to selinexor treatment were not supportive of continued investigation in glioblastoma, therefore Phase 2 data could not be collected and there was no reporting of the Phase 2 data in this report.

Participant flow — Overall Study
MilestoneArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Started231519143
Completed00000
Not completed231519143
Withdrew: Adverse event27010
Withdrew: Physician decision12000
Withdrew: Progressive disease16418113
Withdrew: Study terminated by sponsor01100
Withdrew: Withdrawal by subject31020
Withdrew: Other10000

Outcome measures

PrimaryPhase 1a and 1b: Maximum Tolerated Dose of Selinexor

MTD was defined as highest dose of selinexor in at which no more than one of six participants experienced a dose-limiting toxicity (DLT). DLT was based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Time frame:
At Cycle 1 (up to 42 days)
Reported as:
Number · milligrams per week
Phase 1a and 1b: Maximum Tolerated Dose of Selinexor
milligrams per weekArms A+B+C+D+E: Selinexor
Phase 1a and 1b: Maximum Tolerated Dose of Selinexor60
PrimaryPhase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor

The RP2D was determined by SRC, based on the MTD and the totality of efficacy and safety data of Phase 1a dose escalation study. RP2D was determined based on the totality of the available safety, efficacy, pharmacokinetic/pharmacodynamic (PK/PD).

Time frame:
From Cycle 1 Day 1 up to 14 days after last dose (up to 15.41 months) (Each Cycle length = up to 42 days)
Reported as:
Number · milligrams per week
Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor
milligrams per weekArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor80NANA80NA
PrimaryPhase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEs

TEAE: any event that was not present prior to initiation of study treatment or any event already present that worsened in either intensity or frequency following exposure to study treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose, resulted in death; was life threatening (i.e., an event in which participant was at risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death if it were more severe); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect. Important medical events that might not result in death, was life-threatening, or require hospitalization might be considered serious when, based upon appropriate medical judgment, they might jeopardize participant and might require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From first dose of study treatment up to 30 days post last dose (Up to 16.41 months)
Reported as:
Count of participants · Participants
Phase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEs
ParticipantsArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Participants with Grade >=3 TEAEs15121681
Participants with Serious TEAEs65631
Participants who Discontinued Treatment Due to TEAEs27010
PrimaryPhase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months

Progression defined as first occurrence of disease progression (PD) per modified Response Assessment in Neuro-Oncology (RANO) including both radiological PD and clinical deterioration. PD per RANO response criteria:1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death.

Time frame:
At 3 Months
Reported as:
Number · percentage of participants
Phase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months
percentage of participantsArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months69.666.721.157.133.3
PrimaryPhase 1a and 1b: Overall Survival (OS)

OS was defined as the time from the date of randomization until death due to any cause or until lost to follow-up for all participants.

Time frame:
From date of randomization to the date of death due to any cause or until lost to follow-up (up to 20 months)
Reported as:
Median · months
Phase 1a and 1b: Overall Survival (OS)
monthsArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Overall Survival (OS)13.54 (11.37 to 18.23)19.78 (13.50 to NA)8.34 (7.13 to 12.75)8.80 (6.05 to NA)14.36 (7.20 to NA)
SecondaryPhase 1a and 1b: Time to Progression (TTP)

TTP was defined for participants as the duration from start of treatment to the date of PD, or death due to PD, whichever occurs first. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.

Time frame:
From first dose study treatment until progression or death due to progression (Up to 15.41 months)
Reported as:
Median · months
Phase 1a and 1b: Time to Progression (TTP)
monthsArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Time to Progression (TTP)8.11 (6.05 to 11.50)NA (11.37 to NA)1.38 (1.22 to 4.07)4.60 (2.53 to NA)1.71 (1.64 to NA)
SecondaryPhase 1a and 1b: Progressive Free Survival (PFS)

Progression defined as first occurrence of PD per modified RANO including both radiological PD and clinical deterioration. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.

Time frame:
From first dose of study treatment until progression or death due to any cause (Up to 15.41 months)
Reported as:
Median · months
Phase 1a and 1b: Progressive Free Survival (PFS)
monthsArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Progressive Free Survival (PFS)8.11 (6.05 to 11.50)NA (11.37 to NA)1.38 (1.22 to 4.07)4.60 (2.53 to NA)1.71 (1.64 to NA)
SecondaryPhase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E

ORR was defined as percentage of participants who achieve a CR or PR per modified RANO criteria. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments.

Time frame:
From first dose of study treatment until death due to any cause (Up to 15.41 months)
Reported as:
Number · percentage of participants
Phase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E
percentage of participantsArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E10.5 (1.3 to 33.1)35.7 (12.8 to 64.9)0 (NA to NA)
SecondaryPhase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E

DCR: percentage of participants who achieve CR, PR, or stable disease (SD) per modified RANO criteria. CR: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids. 4) Stable or improved clinical assessments. PR: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3) Steroid dose should be same or lower compared with baseline scan. 4) Stable or improved clinical assessments. SD: 1) Does not qualify for CR, PR, or PD. 2) In event that corticosteroid dose was increased without confirmation of PD on neuroimaging, and subsequent follow-up imaging shows steroid increase was required because of PD, last scan considered to show SD was scan obtained when corticosteroid dose was equivalent to baseline dose.

Time frame:
From first dose of study treatment until death due to any cause (Up to 15.41 months)
Reported as:
Number · percentage of participants
Phase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E
percentage of participantsArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E21.1 (6.1 to 45.6)57.1 (28.9 to 82.3)0 (NA to NA)
SecondaryPhase 1a and 1b: Duration of Response (DOR) in Arm C, D and E

DOR was defined as the time from the date of first evidence of objective response (CR or PR) until PD. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments. DOR was analyzed by Kaplan-Meier for participants who have achieved overall response (CR or PR).

Time frame:
From the date of first evidence of objective response until progression (Up to 15.41 months)
Reported as:
Median · months
Phase 1a and 1b: Duration of Response (DOR) in Arm C, D and E
monthsArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
Phase 1a and 1b: Duration of Response (DOR) in Arm C, D and ENA (3.02 to NA)3.52 (2.79 to NA)—
SecondaryPhase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor

Cmax of Selinexor was reported.

Time frame:
Cycle 1 Day 1: 2, 4, and 6 hours post-dose (Cycle 1 length = up to 42 days)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Phase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor
nanograms per milliliter (ng/mL)Selinexor 40 mgSelinexor 60 mgSelinexor 80 mg
Phase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor306 ± 17.8490 ± 35.9607 ± 32.3

Adverse events

Collected over From first dose of study treatment up to 30 days post last dose (Up to 20 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Selinexor + Radiation Therapy15/23 (65.2%)6/23 (26.1%)23/23 (100%)
Arm B: Selinexor + Temozolomide + Radiation Therapy7/15 (46.7%)5/15 (33.3%)15/15 (100%)
Arm C: Selinexor + Lomustine/Carmustine15/19 (78.9%)6/19 (31.6%)19/19 (100%)
Arm D: Selinexor + Bevacizumab11/14 (78.6%)3/14 (21.4%)14/14 (100%)
Arm E: Selinexor + Tumor Treating Fields3/3 (100%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
HeadacheNervous system disorders0/230/150/190/141/3
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/230/151/190/140/3
SeizureNervous system disorders2/230/150/190/140/3
Febrile neutropeniaBlood and lymphatic system disorders0/231/150/191/140/3
DizzinessNervous system disorders0/230/151/191/140/3
Non-cardiac chest painGeneral disorders0/230/150/191/140/3
OverdoseInjury, poisoning and procedural complications0/230/150/191/140/3
Postoperative wound infectionInfections and infestations0/230/150/191/140/3
Traumatic intracranial haemorrhageInjury, poisoning and procedural complications0/230/150/191/140/3
AgitationMetabolism and nutrition disorders0/231/150/190/140/3
Most frequent other events
Showing 10 of 57
Most frequent other events
EventArm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating Fields
FatigueGeneral disorders21/2314/1514/196/142/3
ThrombocytopeniaBlood and lymphatic system disorders6/2310/1515/197/141/3
NeutropeniaBlood and lymphatic system disorders12/2311/1511/196/140/3
Oedema peripheralGeneral disorders2/230/154/192/142/3
NauseaGastrointestinal disorders14/239/157/197/140/3
LymphopeniaBlood and lymphatic system disorders8/239/1510/193/141/3
LeukopeniaBlood and lymphatic system disorders8/235/158/198/140/3
ConstipationGastrointestinal disorders12/237/153/194/141/3
Weight decreasedInvestigations10/235/151/194/140/3
Weight increasedInvestigations10/235/151/194/140/3

Baseline characteristics

The safety population consisted of participants who have been assigned to study intervention and who have received \>=1 dose of study drug. Due to the early study termination and pre-specified analysis, data was collected/reported according to disease characteristics and combined dose range (60 to 80 mg or 40 to 80 mg) participants received regardless of study phase. The 'per arm' or 'per dose level' data was not collected.

Age, Continuous
Age, Continuous(years)Arm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating FieldsTotal
Mean60.6 ± 13.8453.3 ± 14.8859.2 ± 10.2259.0 ± 10.5053.3 ± 2.5257.7 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating FieldsTotal
Female11794132
Male1281010242
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating FieldsTotal
Hispanic or Latino6214114
Not Hispanic or Latino17131710259
Unknown or Not Reported001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Selinexor + Radiation TherapyArm B: Selinexor + Temozolomide + Radiation TherapyArm C: Selinexor + Lomustine/CarmustineArm D: Selinexor + BevacizumabArm E: Selinexor + Tumor Treating FieldsTotal
American Indian or Alaska Native000000
Asian010001
Native Hawaiian or Other Pacific Islander000000
Black or African American012104
White23121613367
More than one race000000
Unknown or Not Reported011002
08

Study locations

18 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center)
    Los Angeles, California 90033, United States
  • University of California
    San Francisco, California 94122, United States
  • Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive
    Miami, Florida 33176, United States
  • Piedmont Healthcare
    Atlanta, Georgia 30309, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Hackensack Meridian Health, 92 Second Street
    Hackensack, New Jersey 07601, United States
  • Atlantic Health Systems Hospital Corp.
    Morristown, New Jersey 07960, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Lenox Hill Hospital-Northwell Health
    New York, New York 10075, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah - Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Washington - Alvord Brain Tumor Center
    Seattle, Washington 98109, United States
  • Princess Margaret Hospital (PMH)
    Toronto, Ontario M5G 2MG, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2023, 36 months.

Results were first posted in Dec 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 9, 2020
StartActual
Jun 8, 2020
Primary completionActual
Jul 3, 2023
CompletionActual
Jul 3, 2023
Results first posted
Dec 16, 2024
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04421378
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jun 8, 2020
Primary completion
Jul 3, 2023
Completion
Jul 3, 2023
Results posted
Dec 16, 2024
Last update
Dec 16, 2024

Study contacts

Andrew B Lassman, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · Temozolomide · Lomustine · Carmustine

Start the discussion